Nureca discloses manual share buy by director Smita Goyal

1 min read     Updated on 11 Aug 2026, 09:13 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Nureca Limited manually disclosed share purchases by director Smita Goyal under PIT Regulations after automated systems failed. Goyal bought ₹14.2 million worth of shares between July 24 and 31, 2026, raising her stake to 0.47%. The largest purchase was ₹6.3 million on July 27.

powered bylight_fuzz_icon
48008594

*this image is generated using AI for illustrative purposes only.

nureca has manually disclosed share acquisitions by its designated person, Smita Goyal, after the company’s automated system-driven disclosure mechanism failed to reflect the transactions. The disclosure, made under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, ensures regulatory compliance despite technical glitches that prevented automatic reporting to stock exchanges.

The company initially attributed the non-reflection of transactions to possible delays in internal system processing. However, after further verification and communication with the respective stock exchanges, no conclusive resolution was received. As a precautionary measure, Nureca Limited submitted the disclosure manually to ensure adherence to insider trading regulations. The company continues to coordinate with exchanges to resolve the system issue.

Smita Goyal, categorized as a Director and Promoter Group member, acquired equity shares on multiple dates in late July 2026. The transactions were executed on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). Her total holding increased from 0.00% to 0.47% during this period.

Date Exchange Shares Acquired Value (₹) Post-Transaction Holding Holding %
July 24, 2026 NSE 5,975 1,799,371.25 5,982 0.06%
July 24, 2026 BSE 800 240,280.35 6,782 0.07%
July 27, 2026 NSE 20,355 6,327,962.40 27,137 0.28%
July 28, 2026 NSE 6,500 2,017,990.00 33,637 0.35%
July 29, 2026 NSE 8,000 2,545,920.00 41,637 0.44%
July 29, 2026 BSE 1,000 323,225.30 42,637 0.45%
July 31, 2026 NSE 2,683 868,970.04 45,320 0.47%

The total value of shares acquired by Smita Goyal amounts to ₹14,223,419.34. All transactions were conducted on-market, as per the disclosure form. No derivative trading was reported by the designated person during this period.

What the Numbers Show

The acquisition pattern indicates significant buying activity over a concentrated seven-day window. The largest single transaction occurred on July 27, 2026, where 20,355 shares were purchased for ₹6,327,962.40, accounting for nearly 45% of the total value acquired during this period. This suggests a deliberate accumulation strategy by the promoter group member rather than routine trading.

Historical Stock Returns for Nureca

1 Day5 Days1 Month6 Months1 Year5 Years
-3.04%-2.79%+38.99%+11.72%+35.89%-80.12%

Will the technical failure in Nureca's automated disclosure system trigger a regulatory audit or penalties from SEBI regarding compliance infrastructure?

Does Smita Goyal's rapid accumulation of 0.47% equity signal an upcoming strategic shift, merger, or positive internal developments at Nureca?

How might this manual disclosure incident impact investor confidence in Nureca's corporate governance and operational reliability?

Nureca Limited concludes GST dispute with ₹15.4 lakh payment

1 min read     Updated on 07 Aug 2026, 12:21 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Nureca Limited resolved a GST dispute for the 2021-22 period by reversing Input Tax Credit worth Rs. 15,40,311. The Final Order of Rectification under the CGST Act confirms no further demands exist. The disclosure was made under SEBI LODR Regulations.

powered bylight_fuzz_icon
47631059

*this image is generated using AI for illustrative purposes only.

Nureca Limited has concluded a pending Goods and Services Tax (GST) dispute by receiving a Final Order of Rectification under Section 161 of the CGST Act, 2017. The resolution pertains to a tax order for the period 2021-22 and was finalized on August 07, 2026, following the payment of outstanding dues. This closure eliminates any further regulatory demand from the concerned authority regarding this specific tax period.

The settlement was achieved through the reversal of Input Tax Credit (ITC) rather than a cash outflow, preserving the company’s immediate liquidity position. The total value of the dues settled amounted to Rs. 15,40,311. By opting for ITC reversal, Nureca Limited addressed the compliance requirement while managing its working capital efficiently, a common strategy in indirect tax disputes where credit balances are available.

Settlement Details

The financial impact of the resolution is limited to the reversal of tax credits, as detailed below:

Particulars Amount
Dues Paid via ITC Reversal Rs. 15,40,311
Tax Period Covered 2021-22
Regulatory Framework CGST Act, 2017

Regulatory Disclosure

Nureca Limited made this disclosure pursuant to Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was issued to both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) to ensure transparency with investors. The notice was signed by Nishu Kansal, Company Secretary & Compliance Officer, confirming that the matter stands fully concluded with no further liabilities arising from the original order.

What the Numbers Show

The use of Input Tax Credit reversal to settle the Rs. 15,40,311 liability indicates that the dispute did not result in an additional cash burden for the company. In GST litigation, settlements often involve penalties or interest payments in cash; however, a pure ITC reversal suggests the core issue was likely related to the eligibility or matching of input credits rather than a fundamental evasion of tax liability. This outcome neutralizes the regulatory risk associated with the 2021-22 period without impacting the company’s cash flow statement.

Historical Stock Returns for Nureca

1 Day5 Days1 Month6 Months1 Year5 Years
-3.04%-2.79%+38.99%+11.72%+35.89%-80.12%

How might the successful resolution of this GST dispute influence Nureca Limited's future tax compliance strategies and internal audit processes?

Could the precedent set by settling via Input Tax Credit reversal encourage other pharmaceutical companies to adopt similar non-cash settlement methods for indirect tax disputes?

What impact, if any, will the removal of this regulatory overhang have on Nureca Limited's credit ratings or investor sentiment regarding its operational risk profile?

More News on Nureca

1 Year Returns:+35.89%